Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.43 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10326897 | 1.00 | SLC6A4 (0.43) | SLC6A4SLC6A3UGT2B7SLC6A2ADRA2A | |
| SCHEMBL10326262 | 1.00 | SLC6A4 (0.43) | SLC6A4SLC6A3UGT2B7SLC6A2ADRA2A | |
| SCHEMBL12295130 | 0.88 | NR1H4 (0.45) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL25974591 | 0.86 | HIF1A (0.57) | UGT2B7MAPTHIF1AHSD17B10 | |
| Hydrochloric Acid SCHEMBL20482086 | 0.84 | HIF1A (0.56) | UGT2B7MAPTHIF1AHSD17B10 | |
| Hydrochloric Acid SCHEMBL20482083 | 0.84 | HIF1A (0.56) | UGT2B7MAPTHIF1AHSD17B10 | |
| SCHEMBL3173810 | 0.81 | HIF1A (0.64) | SLC6A4SLC6A3SLC6A2MAPTHIF1A | |
| SCHEMBL2844473 | 0.79 | SLC6A3 (0.53) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL2842321 | 0.79 | SLC6A3 (0.53) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL670331 | 0.79 | SLC6A3 (0.53) | SLC6A4SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438989-B1 | USE OF ASYMMETRIC HYDROGENATION CATALYST | TAKASAGO PERFUMERY CO LTD (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-8217204-B2 | Catalyst for asymmetric hydrogenation | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-12-23 | — | — | US | disclosed |
| WO-2010140636-A1 | ASYMMETRIC HYDROGENATION CATALYST | 高砂香料工業株式会社 (JP) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324338-A1 | CATALYST FOR ASYMMETRIC HYDROGENATION | H1-0, H1-5, ADH5 | SLC6A4 4697/4885SLC6A3 4843/4885UGT2B7 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.